Edwards Lifesciences Corp (NYSE: EW) has reported earnings for its fourth fiscal quarter (ending December 31) of $0.58 versus $0.55 for the same period a year ago — an increase of 5%. This performance was $0.03 better than the consensus estimate of $0.56. E.P.S. were $2.34 for the latest four quarters through December 31 versus $2.02 for the same period a year ago — an increase of 16%.
Recent Price Action
Edwards Lifesciences Corp (NYSE: EW) stock declined slightly by -0.3% on 2/11/25. The stock closed at $70.91. However, this decline was accompanied by below average trading volume at 73% of normal. The stock has been weak relative to the market over the last nine months and has declined -0.7% during the last week.
Current PriceTarget Research Rating
Edwards Lifesciences has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Edwards Lifesciences has a poor Appreciation Score of 29 and a poor Power Rating of 27, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment